Medtronic plans to spin out its diabetes business due to increased competition in the market. Other companies have already received FDA authorization for insulin pumps and CGMs for Type 2 diabetes, challenging Medtronic’s position. Insulet leads the U.S. market for insulin pumps and is expanding globally, while Tandem Diabetes Care, Beta Bionics, Sequel MedTech, and Roche are introducing innovative insulin delivery systems and CGMs, increasing market diversity and competition. The evolving landscape indicates a shift towards more advanced and patient-friendly diabetes management solutions, prompting Medtronic’s strategic decision to spin off its diabetes business for better focus and competitiveness.
Read more from medtechdive.com
